mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant

Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Parry, Helen, Tut, Gokhan, Bruton, Rachel, Faustini, Sian, Stephens, Christine, Saunders, Philip, Bentley, Christopher, Hilyard, Katherine, Brown, Kevin, Amirthalingam, Gayatri, Charlton, Sue, Leung, Stephanie, Chiplin, Emily, Coombes, Naomi S, Bewley, Kevin R, Penn, Elizabeth J, Rowe, Cathy, Otter, Ashley, Watts, Rosie, D'Arcangelo, Silvia, Hallis, Bassam, Makin, Andrew, Richter, Alex, Zuo, Jianmin, Moss, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Microbiology and Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500710/
https://www.ncbi.nlm.nih.gov/pubmed/34586068
http://dx.doi.org/10.7554/eLife.69375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500710/
https://www.ncbi.nlm.nih.gov/pubmed/34586068
http://dx.doi.org/10.7554/eLife.69375

Ejemplares similares